Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab - Genentech

X
Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RG7446-42; RO-5541267; TECENTRIQ; Tecentriq SC

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer Amgen; ARCAGY/GINECO Group; Austrian Breast & Colorectal Cancer Study Group; AVEO Oncology; Basilea Pharmaceutica; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Exelixis; Fondazione Michelangelo; Galecto Inc; Genentech; GERCOR; German Breast Group; Gradalis; H. Lee Moffitt Cancer Center and Research Institute; Immune Design; Incyte Corporation; Johns Hopkins University; Kaiser Permanente; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Center (Korea); National Cancer Institute (USA); Netherlands Cancer Institute; NSABP Foundation; Nykode Therapeutics; Oncolytics Biotech; Roche; Roche Pharma AG; Sanofi; University Hospital Southampton NHS Foundation Trust; University Medical Center Groningen; University of California; University of California at San Francisco; University of Florida; University of Oklahoma; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Soft tissue sarcoma; Malignant melanoma; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Urogenital cancer
  • Preregistration Solid tumours
  • Phase III Bladder cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Malignant-mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma
  • Phase II Adrenocortical carcinoma; Anal cancer; Biliary cancer; Brain metastases; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Gynaecological cancer; Head and neck cancer; HER2 positive breast cancer; Malignant thymoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Penile cancer; Phaeochromocytoma; Rectal cancer; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Cholangiocarcinoma; Follicular lymphoma; Gallbladder cancer; Glioblastoma; Hodgkin's disease; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer
  • Phase I Haematological malignancies; Multiple myeloma
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 03 Jun 2024 Hoffmann-La Roche completes a phase II trial in Malignant thymoma (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT04321330)
  • 09 May 2024 Roche plans a regulatory filing for Small cell lung cancer (Combination therapy; Late-stage disease) in 2025 (Roche pipeline, May 2024)
  • 09 May 2024 Roche plans to file regulatory application for Bladder cancer (Adjuvant therapy) in or after 2027 (Roche pipeline, May 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top